A population database study of outcomes associated with Vitamin K antagonists in atrial fibrillation before DOAC

British Journal of Clinical Pharmacology

Volumn 81, Issue 3, 2016, Pages 569-578

  Blin, Patrick ^a,b   Dureau Pournin, Caroline ^a,b   Lassalle, Regis ^a,b   Abouelfath, Abdelilah ^a,b   Droz Perroteau, Cécile ^a,b   Moore, Nicholas ^a,c  

^a Centre of Clinical Investigation Clinical Epidemiology   (France)

^b University of Bordeaux ^*  (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

anticoagulant; atrial fibrillation; cardiovascular outcomes; cohort study; death; population study

Indexed keywords

ACENOCOUMAROL; FLUINDIONE; WARFARIN; ANTICOAGULANT AGENT; VITAMIN K GROUP;

ACUTE CORONARY SYNDROME; ADMINISTRATIVE CLAIMS (HEALTH CARE); ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DEATH; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; SIDE EFFECT; THROMBOSIS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; FACTUAL DATABASE; FRANCE; HEMORRHAGE; HOSPITALIZATION; MIDDLE AGED; MORTALITY; STATISTICS AND NUMERICAL DATA;

ACUTE CORONARY SYNDROME; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; DATABASES, FACTUAL; FEMALE; FRANCE; HEMORRHAGE; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; THROMBOSIS; VITAMIN K;

EID: 84959220156     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12807     Document Type: Article

References (38)

1. Pouyanne P, Haramburu F, Imbs JL, Begaud B,. Admissions to hospital caused by adverse drug reactions: Cross sectional incidence study. French Pharmacovigilance Centres. BMJ 2000; 320: 1036.
2. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM,. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. BMJ 2004; 329: 15-9.
3. Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, Brueckmann M, Pogue J, Alings M, Amerena JV, Avezum A, Baumgartner I, Budaj AJ, Chen JH, Dans AL, Darius H, Di Pasquale G, Ferreira J, Flaker GC, Flather MD, Franzosi MG, Golitsyn SP, Halon DA, Heidbuchel H, Hohnloser SH, Huber K, Jansky P, Kamensky G, Keltai M, Kim SS, Lau CP, Le Heuzey JY, Lewis BS, Liu L, Nanas J, Omar R, Pais P, Pedersen KE, Piegas LS, Raev D, Smith PJ, Talajic M, Tan RS, Tanomsup S, Toivonen L, Vinereanu D, Xavier D, Zhu J, Wang SQ, Duffy CO, Themeles E, Yusuf S,. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation 2013; 128: 237-43.
4. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, Engage Af-Timi Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-104.
5. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA,. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015; 131: 157-64.
6. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, Aristotle Committees, Investigators. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2011; 365: 981-92.
7. Hernandez I, Baik SH, Pinera A, Zhang Y,. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 2015; 175: 18-24.
8. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, Investigators RA,. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
9. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM,. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet 2014; 383: 955-62.
10. Gasse C, Hollowell J, Meier CR, Haefeli WE,. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost 2005; 94: 537-43.
11. Khan F, Datta YH,. Risk of bleeding during long-term anticoagulation with warfarin: A tertiary care center experience. Blood Coagul fibrinolysis 2015; 26: 110-2.
12. Landefeld CS, Goldman L,. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-52.
13. Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merliere Y,. French national health insurance information system and the permanent beneficiaries sample. Revue d'epidemiologie et de sante publique 2010; 58: 286-90.
14. Moulis G, Lapeyre-Mestre M, Palmaro A, Pugnet G, Montastruc JL, Sailler L,. French health insurance databases: What interest for medical research? Rev Med Interne 2015; 36: 411-7.
15. Blin P, Dureau-Pournin C, Foubert-Samier A, Grolleau A, Corbillon E, Jove J, Lassalle R, Robinson P, Poutignat N, Droz-Perroteau C, Moore N,. Parkinson's disease incidence and prevalence assessment in France using the national healthcare insurance database. Eur J Neurol 2015; 22: 464-71.
16. Blin P, Lassalle R, Dureau-Pournin C, Ambrosino B, Bernard MA, Abouelfath A, Gin H, Le Jeunne C, Pariente A, Droz C, Moore N,. Insulin glargine and risk of cancer: A cohort study in the French national healthcare insurance database. Diabetologia 2012; 55: 644-53.
17. Apostolakis S, Lane DA, Buller H, Lip GY,. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial. Thromb Haemost 2013; 110: 1074-9.
18. Dzeshka MS, Lip GY,. Specific risk scores for specific purposes: Use CHA2DS2-VASc for assessing stroke risk, and use HAS-BLED for assessing bleeding risk in atrial fibrillation. Thromb Res 2014; 134: 217-8.
19. Odum LE, Cochran KA, Aistrope DS, Snella KA,. The CHADS(2) versus the new CHA2DS2-VASc scoring systems for guiding antithrombotic treatment of patients with atrial fibrillation: Review of the literature and recommendations for use. Pharmacotherapy 2012; 32: 285-96.
20. Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S,. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013; 128: 2325-32.
21. Redberg RF,. The importance of postapproval data for dabigatran. JAMA Intern Med 2015; 175: 25.
22. Southworth MR, Reichman ME, Unger EF,. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013; 368: 1272-4.
23. Bossavy JP, Sakariassen KS, Thalamas C, Boneu B, Cadroy Y,. Antithrombotic efficacy of the vitamin K antagonist fluindione in a human ex vivo model of arterial thrombosis: Effect of anticoagulation level and combination therapy with aspirin. Arterioscler Thromb Vasc Biol 1999; 19: 2269-75.
24. Lacut K, Ayme-Dietrich E, Gourhant L, Poulhazan E, Andro M, Becquemont L, Mottier D, Le Gal G, Verstuyft C,. Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione. Br J Clin Pharmacol 2012; 73: 428-36.
25. Roncato M, Billaud-Mesguich E, Fiessinger JN, Vitoux JF, Aiach M, Alexandre JM,. Anticoagulant treatment with fluindione. Relation between the decrease of vitamin K-dependent factors and blood fluindione. Therapie 1986; 41: 203-6.
26. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrom SZ, Poulsen HE, Kober L, Torp-Pedersen C,. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170: 1433-41.
27. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, Re-Ly Steering Committee, Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
28. Roskell NS, Samuel M, Noack H, Monz BU,. Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: A systematic review of randomized and observational studies. Europace 2013; 15: 787-97.
29. Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J,. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: Assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. Arch Intern Med 2006; 166: 853-9.
30. Donze J, Rodondi N, Waeber G, Monney P, Cornuz J, Aujesky D,. Scores to predict major bleeding risk during oral anticoagulation therapy: A prospective validation study. Am J Med 2012; 125: 1095-102.
31. Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ, Investigators R-L,. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: A subgroup analysis of the RE-LY trial. Ann Intern Med 2011; 155: 660-7, W204.
32. Roldan V, Marin F, Fernandez H, Manzano-Fernandez S, Gallego P, Valdes M, Vicente V, Lip GY,. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. Chest 2013; 143: 179-84.
33. Witt DM, Delate T, Garcia DA, Clark NP, Hylek EM, Ageno W, Dentali F, Crowther MA,. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med 2012; 172: 1484-91.
34. Slomski A,. Resuming warfarin after GI bleeding leads to better outcomes. JAMA 2014; 311: 349.
35. Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND,. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: Population based cohort study. BMJ 2015; 350: H1857.
36. Jensen PN, Johnson K, Floyd J, Heckbert SR, Carnahan R, Dublin S,. A systematic review of validated methods for identifying atrial fibrillation using administrative data. Pharmacoepidemiol Drug Saf 2012; 21 (Suppl 1): 141-7.
37. Maura G, Blotiere PO, Bouillon K, Billionnet C, Ricordeau P, Alla F, Zureik M,. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: A French nationwide propensity-matched cohort study. Circulation 2015; 132: 1252-60.
38. Chatterjee S, Sardar P, Giri JS, Ghosh J, Mukherjee D,. Treatment discontinuations with new oral agents for long-term anticoagulation: Insights from a meta-analysis of 18 randomized trials including 101,801 patients. Mayo Clin Proc 2014; 89: 896-907.